Source: Health Products Regulatory Authority (ZA) Revision Year: 2022 Publisher: Bayer (Pty) Ltd, Reg. No.: 1968/011192/07, 27 Wrench Road, ISANDO, 1609
MELODENE 0,02 mg/0,075 mg coated tablets.
| Pharmaceutical Form |
|---|
|
Coated tablets. The hormone-containing tablet is small, white round with convex faces. The hormone-free tablet is large, pink round with convex faces. |
Each coated tablet contains ethinylestradiol 0,02 mg and gestodene 0,075 mg.
Excipient: lactose 35 mg and sucrose 20 mg.
Excipient: lactose 45 mg and sucrose 34 mg.
For a full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| 17 alpha-Ethinylestradiol |
Ethinylestradiol is chemically and biologically identical to endogenous human oestradiol. It substitutes for the loss of estrogen production in menopausal women, and alleviates menopausal symptoms. Estrogens prevent bone loss following menopause or ovariectomy. |
|
| Gestodene |
|
| List of Excipients |
|---|
|
Calcium carbonate |
MELODENE is packed in colourless transparent PVC/aluminium blisters containing 21 white hormone-containing tablets plus 7 pink hormone-free tablets per blister strip. The blister strip is packed into an outer cardboard carton.
Pack sizes: 28 tablets and 84 tablets.
Not all pack sizes are marketed.
Bayer (Pty) Ltd, Reg. No.: 1968/011192/07, 27 Wrench Road, ISANDO, 1609
31/18.8/0462
6 April 1998
| Drug | Countries | |
|---|---|---|
| MELODENE | Spain, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
